BIOSYNEX begins safeguard proceedings, AVALUN ceases payment

BIOSYNEX SA has filed a request to open safeguard proceedings to restructure its bank debts with the Strasbourg Judicial Court. This decision comes amid an unfavorable economic climate in the United States and Europe. BIOSYNEX's revenue decreased by 6% in the first half of 2025 compared to 2024, reaching €50.8 million.

At the same time, its subsidiary AVALUN has declared insolvency. AVALUN, acquired in 2021, suffered from the termination of a remote biology project in 2023. Despite the interest generated by its technologies, notably the Tsmart® FIB Batrox test, the company faces significant financial challenges. BIOSYNEX is assessing the financial impacts of this situation, anticipating exceptional amortization of intangible assets and an uncollected receivable of €3.4 million.